Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Stockholders Equity of -$7.66 million for the year ending 2023.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -58.7% in Stockholders Equity from 2022 to 2023.
- This data is from AXIM BIOTECHNOLOGIES, INC.'s annual report (Form 10-K), filed with the SEC on April 16, 2024.
- XBRL data for this metric is available from 2010 to 2023 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $9.7 thousand | Q2 2012: $9.5 thousand | Q3 2012: $11.9 thousand | Q1 2013: -$10.5 thousand | Q2 2013: -$40.3 thousand | Q3 2013: -$51.0 thousand | Q3 2014: -$188.9 thousand | Q4 2014: -$580.7 thousand | Q1 2015: -$1.05 million | Q3 2015: -$762.7 thousand | Q4 2016: -$2.37 million | Q1 2017: -$2.90 million | Q4 2019: -$6.76 million | Q1 2020: -$361.7 thousand | Q2 2020: $999.1 thousand | Q3 2020: $2.29 million | Q1 2021: $1.63 million | Q2 2021: $1.04 million | Q3 2021: $4.65 million | Q1 2022: -$3.42 million | Q2 2022: -$3.73 million | Q3 2022: -$4.38 million | Q4 2022: -$4.83 million | Q1 2023: -$6.16 million | Q2 2023: -$9.75 million | Q3 2023: -$5.96 million | Q4 2023: -$7.66 million | Q1 2024: -$7.45 million | Q2 2024: -$9.53 million.
- Historical annual values: Fiscal year 2023: -$7.66 million | Fiscal year 2022: -$4.83 million | Fiscal year 2021: -$2.34 million | Fiscal year 2020: $1.57 million | Fiscal year 2014: -$580.7 thousand | Fiscal year 2013: -$93.9 thousand | Fiscal year 2012: -$4.7 thousand | Fiscal year 2011: $10.2 thousand | Fiscal year 2010: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: